Literature DB >> 30258147

Antibodies pose a double threat to HIV.

Nancy L Haigwood.   

Abstract

Keywords:  Immunology; Medical research

Mesh:

Substances:

Year:  2018        PMID: 30258147     DOI: 10.1038/d41586-018-06773-8

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  20 in total

1.  Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Authors:  Marina Caskey; Florian Klein; Julio C C Lorenzi; Michael S Seaman; Anthony P West; Noreen Buckley; Gisela Kremer; Lilian Nogueira; Malte Braunschweig; Johannes F Scheid; Joshua A Horwitz; Irina Shimeliovich; Sivan Ben-Avraham; Maggi Witmer-Pack; Martin Platten; Clara Lehmann; Leah A Burke; Thomas Hawthorne; Robert J Gorelick; Bruce D Walker; Tibor Keler; Roy M Gulick; Gerd Fätkenheuer; Sarah J Schlesinger; Michel C Nussenzweig
Journal:  Nature       Date:  2015-04-08       Impact factor: 49.962

Review 2.  Use of broadly neutralizing antibodies for HIV-1 prevention.

Authors:  Amarendra Pegu; Ann J Hessell; John R Mascola; Nancy L Haigwood
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

3.  Multiple Origins of Virus Persistence during Natural Control of HIV Infection.

Authors:  Eli A Boritz; Samuel Darko; Luke Swaszek; Gideon Wolf; David Wells; Xiaolin Wu; Amy R Henry; Farida Laboune; Jianfei Hu; David Ambrozak; Marybeth S Hughes; Rebecca Hoh; Joseph P Casazza; Alexander Vostal; Daniel Bunis; Krystelle Nganou-Makamdop; James S Lee; Stephen A Migueles; Richard A Koup; Mark Connors; Susan Moir; Timothy Schacker; Frank Maldarelli; Stephen H Hughes; Steven G Deeks; Daniel C Douek
Journal:  Cell       Date:  2016-07-21       Impact factor: 41.582

4.  Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.

Authors:  J E Ledgerwood; E E Coates; G Yamshchikov; J G Saunders; L Holman; M E Enama; A DeZure; R M Lynch; I Gordon; S Plummer; C S Hendel; A Pegu; M Conan-Cibotti; S Sitar; R T Bailer; S Narpala; A McDermott; M Louder; S O'Dell; S Mohan; J P Pandey; R M Schwartz; Z Hu; R A Koup; E Capparelli; J R Mascola; B S Graham
Journal:  Clin Exp Immunol       Date:  2015-09-24       Impact factor: 4.330

5.  HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.

Authors:  Johannes F Scheid; Joshua A Horwitz; Yotam Bar-On; Edward F Kreider; Ching-Lan Lu; Julio C C Lorenzi; Anna Feldmann; Malte Braunschweig; Lilian Nogueira; Thiago Oliveira; Irina Shimeliovich; Roshni Patel; Leah Burke; Yehuda Z Cohen; Sonya Hadrigan; Allison Settler; Maggi Witmer-Pack; Anthony P West; Boris Juelg; Tibor Keler; Thomas Hawthorne; Barry Zingman; Roy M Gulick; Nico Pfeifer; Gerald H Learn; Michael S Seaman; Pamela J Bjorkman; Florian Klein; Sarah J Schlesinger; Bruce D Walker; Beatrice H Hahn; Michel C Nussenzweig; Marina Caskey
Journal:  Nature       Date:  2016-06-22       Impact factor: 49.962

6.  Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.

Authors:  Katharine J Bar; Michael C Sneller; Linda J Harrison; J Shawn Justement; Edgar T Overton; Mary E Petrone; D Brenda Salantes; Catherine A Seamon; Benjamin Scheinfeld; Richard W Kwan; Gerald H Learn; Michael A Proschan; Edward F Kreider; Jana Blazkova; Mark Bardsley; Eric W Refsland; Michael Messer; Katherine E Clarridge; Nancy B Tustin; Patrick J Madden; KaSaundra Oden; Sijy J O'Dell; Bernadette Jarocki; Andrea R Shiakolas; Randall L Tressler; Nicole A Doria-Rose; Robert T Bailer; Julie E Ledgerwood; Edmund V Capparelli; Rebecca M Lynch; Barney S Graham; Susan Moir; Richard A Koup; John R Mascola; James A Hoxie; Anthony S Fauci; Pablo Tebas; Tae-Wook Chun
Journal:  N Engl J Med       Date:  2016-11-09       Impact factor: 91.245

7.  Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects.

Authors:  Adelzon A Paula; Melissa Cn Falcão; Antonio G Pacheco
Journal:  AIDS Res Ther       Date:  2013-12-13       Impact factor: 2.250

Review 8.  Targeting the Latent Reservoir for HIV-1.

Authors:  Srona Sengupta; Robert F Siliciano
Journal:  Immunity       Date:  2018-05-15       Impact factor: 31.745

9.  Combination therapy with anti-HIV-1 antibodies maintains viral suppression.

Authors:  Pilar Mendoza; Henning Gruell; Florian Klein; Marina Caskey; Michel C Nussenzweig; Lilian Nogueira; Joy A Pai; Allison L Butler; Katrina Millard; Clara Lehmann; Isabelle Suárez; Thiago Y Oliveira; Julio C C Lorenzi; Yehuda Z Cohen; Christoph Wyen; Tim Kümmerle; Theodora Karagounis; Ching-Lan Lu; Lisa Handl; Cecilia Unson-O'Brien; Roshni Patel; Carola Ruping; Maike Schlotz; Maggi Witmer-Pack; Irina Shimeliovich; Gisela Kremer; Eleonore Thomas; Kelly E Seaton; Jill Horowitz; Anthony P West; Pamela J Bjorkman; Georgia D Tomaras; Roy M Gulick; Nico Pfeifer; Gerd Fätkenheuer; Michael S Seaman
Journal:  Nature       Date:  2018-09-26       Impact factor: 49.962

10.  Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.

Authors:  Yotam Bar-On; Henning Gruell; Till Schoofs; Joy A Pai; Lilian Nogueira; Allison L Butler; Katrina Millard; Clara Lehmann; Isabelle Suárez; Thiago Y Oliveira; Theodora Karagounis; Yehuda Z Cohen; Christoph Wyen; Stefan Scholten; Lisa Handl; Shiraz Belblidia; Juan P Dizon; Jörg J Vehreschild; Maggi Witmer-Pack; Irina Shimeliovich; Kanika Jain; Kerstin Fiddike; Kelly E Seaton; Nicole L Yates; Jill Horowitz; Roy M Gulick; Nico Pfeifer; Georgia D Tomaras; Michael S Seaman; Gerd Fätkenheuer; Marina Caskey; Florian Klein; Michel C Nussenzweig
Journal:  Nat Med       Date:  2018-09-26       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.